(Health Korea News / Lee Si-woo) The three largest shareholders of Hanmi Science (Hanyang Precision Chairman Shin Dong-guk, Hanmi Pharmaceutical Group Chairman Song Young-sook and Vice Chairman Lim Joo-hyun) are joining the recently controversial financing plan of the brothers (executive director Lim Jong-yoon and CEO Lim Jong-hoon). Regarding this, he said, “The three-person alliance will never make inappropriate attempts such as a ‘paid-in capital increase’ that forces shareholders to make unilateral sacrifices.”
The three-person alliance said in a statement on the weekend of the 15th, “As we have united for the true stabilization of the company, we seek to quickly stabilize management by reforming Hanmi Pharmaceutical Group’s governance centered on a professional management system.” “For this to happen, a special resolution to change the Articles of Incorporation must be passed at this extraordinary general meeting (on the 28th),” he emphasized.
The three-member alliance said, “The brothers’ dictatorial management behavior is worsening day by day, and the stock value of Hanmi Science is continuously plummeting due to this management behavior,” and added, “We must use the power of shareholders at this extraordinary shareholders’ meeting to quickly stop such behavior.” “Please collect them,” he appealed.
The three-member alliance continued, “Hanmi Science’s management revealed the need for an investment of 800 billion won through a press conference on the 8th, but remained silent about the specific plan to raise funds, leaving several suspicions,” adding, “In the industry, the brothers are forcing shareholders to make sacrifices.” “This is raising suspicions that the company is considering capital increase with paid-in capital and various financing methods,” he claimed. (See related article below)
At the same time, he strengthened his determination, saying, “We will block these attempts by the brothers through a special resolution and regain our true value as the holding company of Hanmi Pharmaceutical Group, which has led the domestic pharmaceutical industry.”
The three-person alliance said, “Amid the ongoing dispute over the past year, wise judgment and support from minority shareholders is more urgent than ever,” and added, “Anything that damages the value of Hanmi Pharmaceutical Group and damages shareholders’ assets, such as paid-in capital increase.” “We will definitely pass a special resolution to prevent this from happening,” he pledged.
The three-person alliance promised, “As soon as management rights are stabilized, we will find and implement various ways to communicate with minority shareholders on a regular basis.”
The three-member alliance said, “Despite the reckless attacks from the brothers who are going beyond the golden limit, we will focus only on gathering all voting rights without wavering, and with the voting rights gathered, we will create shareholder value through the speedy launch of innovative new drugs such as obesity treatments and practical management results.” “We will focus on laying the foundation for improvement,” he said, and repeatedly appealed to shareholders, “Please join forces to pass a special resolution at this extraordinary shareholders’ meeting.”
Copyright © Health Korea News Unauthorized reproduction and redistribution prohibited
Source: www.hkn24.com
